Association of the Low-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Ratio and Body Mass Index with Coronary Plaque Regression

被引:0
|
作者
Tani, Shigemasa [1 ,2 ]
Matsumoto, Michiaki [2 ]
Nakamura, Yasutaka [2 ]
Nagao, Ken [2 ]
Hirayama, Atsushi [2 ]
机构
[1] Nihon Univ, Surugadai Hosp, Dept Cardiol, Chiyoda Ku, Tokyo 1018309, Japan
[2] Nihon Univ, Sch Med, Dept Med, Div Cardiol, Tokyo 1018309, Japan
关键词
RANDOMIZED CONTROLLED-TRIAL; INTRAVASCULAR ULTRASOUND; STATIN THERAPY; CARDIOVASCULAR EVENTS; PRAVASTATIN TREATMENT; JAPAN ASSESSMENT; ARTERY-DISEASE; ATHEROSCLEROSIS; ATORVASTATIN; PITAVASTATIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The change (Delta) in the low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio (Delta LDL-C/HDL-C) and obesity are known to play important roles in the progression of coronary atherosclerosis. We hypothesized that a reasonable predictive model of coronary plaque regression could be constructed using Delta LDL-C/HDL-C and the body mass index(BMI). Objective: The purpose of this study was to establish a predictive model of coronary plaque regression using Delta LDL-C/HDL-C and BMI. Methods and Results: A 6-month prospective observational study was conducted among 114 patients with coronary artery disease (CAD) who were treated with pravastatin. The plaque volume, as assessed using volumetric intravascular ultrasound, decreased significantly by 9.9% (p < 0.0001 vs baseline). In a multivariate regression analysis with traditional risk factors, Delta LDL-C/HDL-C (beta: 0.473, p = 0.0001) and the baseline BMI (beta: 0.249, p = 0.004) were identified as independent predictors of the Delta plaque volume. The patients were divided using the 50th percentile of the baseline BMI and the 50th percentile of the Delta LDL-C/HDL-C ratio as cutoffs, and a model for predicting coronary atherosclerotic regression was prepared using a combination of the two variables. The Delta plaque volumes were -18.3%, -14.1%, -4.8%, and -2.2% for the groups with Delta LDL-C/HDL-C <= -22.2% and a BMI <= 24.1 kg/m(2), Delta LDL-C/HDL-C <= -22.2% and Delta BMI >24.1 kg/m(2), Delta LDL-C/HDL-C > -22.2% and BMI <= 24.1 kg/m(2), and Delta LDL-C/HDL-C > -22.2% and BMI >24.1 kg/m(2), respectively (p = 0.003). Conclusion: A predictive model for coronary plaque regression based on a combination of Delta LDL-C/HDL-C and the baseline BMI may be a useful clinical tool in patients with CAD.
引用
收藏
页码:279 / 286
页数:8
相关论文
共 50 条
  • [41] Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes
    Khang, Ah Reum
    Song, Young Shin
    Kim, Kyoung Min
    Moon, Jae Hoon
    Lim, Soo
    Park, Kyong Soo
    Jang, Hak Chul
    Choi, Sung Hee
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (03) : 528 - 537
  • [42] Relationship between non-high-density lipoprotein cholesterol/apolipoprotein A-I and monocyte/high-density lipoprotein cholesterol ratio and coronary heart disease
    Li, Ya
    Li, Shu
    Ma, Yulin
    Li, Jialing
    Lin, Mingying
    Wan, Jing
    CORONARY ARTERY DISEASE, 2020, 31 (07) : 623 - 627
  • [43] Fasting non-high-density lipoprotein cholesterol and low-density lipoprotein particle size
    Arisaka, Osamu
    Kariya, Katsura
    Ichikawa, Go
    JOURNAL OF PEDIATRICS, 2012, 160 (03) : 531 - 532
  • [44] Associations of non-high-density lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population
    Wen, Jia
    Huang, Yun
    Lu, Yao
    Yuan, Hong
    HYPERTENSION RESEARCH, 2019, 42 (08) : 1223 - 1230
  • [45] Relation of High-Density Lipoprotein Cholesterol to Mortality After Percutaneous Coronary Interventions in Patients With Low-Density Lipoprotein &lt;70 mg/dl
    Kini, Annapoorna S.
    Muntner, Paul
    Moreno, Pedro R.
    Mann, Devin
    Krishnan, Prakash
    Kim, Michael C.
    Rafael, Oana C.
    Farkouh, Michael E.
    Sharma, Samin K.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (03) : 350 - 354
  • [46] Alirocumab for low-density lipoprotein cholesterol lowering
    Roth, Eli M.
    FUTURE CARDIOLOGY, 2019, 15 (01) : 17 - 29
  • [47] Impact of the Low- to High-Density Lipoprotein Cholesterol Ratio on Composition of Angiographically Ambiguous Left Main Coronary Artery Plaque
    Kurebayashi, Nobutake
    Yoshikawa, Daiji
    Ishii, Hideki
    Sato, Bummei
    Ando, Hirohiko
    Okada, Takuya
    Hayakawa, Seiichi
    Okumura, Naoki
    Isobe, Satoshi
    Takeshita, Kyosuke
    Hayashi, Mutsuharu
    Uetani, Tadayuki
    Amano, Tetsuya
    Murohara, Toyoaki
    CIRCULATION JOURNAL, 2011, 75 (08) : 1960 - 1967
  • [48] What is the Optimal Low-Density Lipoprotein Cholesterol?
    Gagel, Andrew
    Zghyer, Fawzi
    Samuel, Christeen
    Martin, Seth S.
    MEDICAL CLINICS OF NORTH AMERICA, 2022, 106 (02) : 285 - +
  • [49] Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
    Willeit, Peter
    Yeang, Calvin
    Moriarty, Patrick M.
    Tschiderer, Lena
    Varvel, Stephen A.
    McConnell, Joseph P.
    Tsimikas, Sotirios
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (23):
  • [50] The relationship between triglyceride/high-density lipoprotein cholesterol ratio and coronary microvascular disease
    Liao, Li Ping
    Wu, Lei
    Yang, Yang
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)